

# Early Detection of Breast Cancer: Synthesis and Characterization of Novel Target Specific NIR-Fluorescent Estrogen Conjugate for Molecular Optical Imaging

Iven Jose · Kodand Dinakar Deodhar · Uday B. Desai · Shubhadeep Bhattacharjee

Received: 30 September 2010 / Accepted: 28 December 2010 / Published online: 8 January 2011  
© Springer Science+Business Media, LLC 2011

**Abstract** Estrogen induced proliferation of existing mutant cells is widely understood to be the major risk determining factor in the development of breast cancer. Hence determination of the Estrogen Receptor[ER] status is of paramount importance. We have carried out the synthesis and characterization of a novel NIR fluorescent dye conjugate aimed at measuring ER+ve status in-vivo. The conjugate was synthesized by ester formation between 17- $\beta$  estradiol and a cyanine dye namely: bis-1, 1-(4-sulfobutyl) indotricarbocyanine-5-carboxylic acid, sodium salt. The replacement of the sodium ion in the ester by a larger glucosammonium ion was found to enhance the hydrophilicity and reduce the toxic effect on cell lines. The excitation and emission peaks for the dye were recorded as 750 and 788 nm respectively; ideal for non-invasive optical imaging owing to minimal tissue attenuation and auto-fluorescence at these wavelengths. The dye (**NIRDC1**) has a significant drop in plasma-

protein binding therefore leading to marked improvement in pharmacokinetic profile such as dye evacuation in comparison to ICG. In addition the dye showed enhanced fluorescence quantum yield, molar extinction coefficient and linearity in fluorescence relative to ICG. This dye can be potentially used as a target specific exogenous contrast agent in molecular optical imaging for early detection of breast cancer.

**Keywords** Breast cancer · Estrogen receptor status · NIR fluorescent dye · Estrogen conjugate · Fluorescence molecular optical imaging · NIRD1 conjugate (NIRDC1)

## Introduction

Many factors both genetic and hormonal have been cited to initiate and sustain breast cancer. The main estrogenic hormone, 17 $\beta$ -estradiol through the E2 action is mediated by transcriptional actions of the nuclear estrogen receptors, ER $\alpha$  and ER $\beta$  thus stimulating excessive cell growth in cancerous adenocarcinoma breast tissues [1]. This accounts for over 70% of all breast cancers and is termed ER+ve meaning that a significant number of cancer cells have ER present [23]. Thus the determination of ER status plays a crucial role in cancer prognosis, deciding the extent of cancer pathogenesis and treatment regime for breast cancer patients [1, 2, 3]. Unfortunately only invasive techniques such as immuno-histochemistry and steroid binding array studies which are based on collection of tissue samples through biopsy are present for ER status determination, which is a rather expensive and painful affair. This opens up a challenging proposition of developing non-invasive, possibly in-vivo diagnosis scheme for determination of


I. Jose · S. Bhattacharjee (✉)  
Department of Electrical and Electronics Engineering,  
Birla Institute of Technology and Science,  
Pilani–K. K. Birla Goa Campus,  
Zuarinagar, Goa 403726, India  
e-mail: bhattacharjee.shubhadeep@gmail.com

K. D. Deodhar  
Department of Chemistry,  
Indian Institute of Technology-Bombay,  
Powai,  
Mumbai, India 400076

U. B. Desai  
Department of Electrical Engineering,  
Indian Institute of Technology-Bombay,  
Powai,  
Mumbai, India 400076

estrogen receptor status and other bio-molecular functions central to cancer pathogenesis. Surely, these developments will prove vital in not only early detection and hence early cure but also risk determination of cancer.

Non-invasive imaging with diffusive photon migration represents an intriguing avenue for extracting biological information from living subjects [4]. While light in the visible range is routinely used for intravital microscopy, imaging of deeper tissues requires the use of near-infrared (NIR) light (700–900 nm), as hemoglobin and water, the major absorbers of visible and infrared light, respectively, have their lowest attenuation and auto-fluorescence in this region (Fig. 1). Light photons can be used to measure different native parameters of tissue through which they travel, such as absorption, scattering, polarization, spectral characteristics, and fluorescence [9]. Exogenously added contrast agents would aid in the specificity and sensitivity of disease detection apart from contrast enhancement. It has been evident that fluorescence spectroscopy of the endogenous compounds can provide enhanced contrast as well as diagnostic information [11, 13, 26]. It has also been shown that exogenous dyes may offer the best contrast for optical imaging [18, 19, 20]. The benefit of specific targeting is apparent: high selectivity and affinity of receptor ligands enable the use of low (nanomolar) doses of the compounds, which result in a high signal to noise ratio. Tumor exhibit distinctive metabolite alteration, this ability to extract tissue functional information may offer a unique way to non-invasively differentiate between benign and malignant tumors [18, 19]. While a non target specific dye indocyanine green (ICG) has been used clinically for over 20 years with few side effects [5, 22] its use in designing targeted agents is limited primarily because of the non-availability of monoderivatized activated precursors.



**Fig. 1** Absorption of major chromophores in the NIR window

In the recent years different groups have illustrated and synthesized several new derivatives such as tricarbocyanines [7] and cyptates [8]. It has been studied that by structural modification of indocyanine green, a variety of novel cyanine dyes with different degrees of hydrophilicity and molecular weight can be generated. By systematic structural modifications on the exterior ring of bis-1,1-(4-sulfobutyl) indotricarbocyanine chromophore a class of new NIRF dyes can be obtained [27] (Fig. 2).

We have synthesized a novel functionalized Estrogen conjugate form carbocyanine dye. The ester functional groups present here are reactive toward primary amines and can be used as fluorescent probes. Additional disadvantages of ICG such as hydrophobicity, high albumin (plasma-protein) binding, nonlinear fluorescence, and other intrinsic properties [6, 24, 25] are also considerably reduced. This technique offers potential of non-invasive detection of the hormone receptor status *in-vivo* and helps in decreasing the load of unnecessary biopsies.


## Materials and Methods

### Base Chemicals and Reagents


All chemicals and solvents used for chemical reaction were reagent grade. Analytical grade solvents were used for chromatographic purification. Glutaconic aldehyde dianilide, 2,3,3-trimethyl-3H-indolenine, 1,4-butanediol—Lancaster, Isopropyl methyl ketone—Merck, 17-β estradiol—Sigma-Aldrich Ltd., Indion ion exchange resins were purchased from Indian Chemicals Ltd. Reactions were monitored by doing thin layer chromatography. All other reagents were purchased from Sigma Aldrich. 5-carboxy-1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine [10] and 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine [12] were synthesized according to the literature [14, 15] and Bis-1,1′-(4-sulfobutyl)indotricarbocyanine-5-carboxylic acid, sodium salt was synthesized according to the literature [1] (Fig. 3).

### Tagging of 17-β Estradiol to NIRD1

In a typical experiment, 10 mg of dye, 30 μL of Dicyclohexylcarbodiimide (DCC), 50 μL of 4-DimethylAminoPyridine




**Fig. 2** Structure of NIRD1 fluochrome


**Fig. 3** Synthesis of NIRD1 fluochrome

(DMAP), 22 mg of 17- $\beta$  Estradiol and 0.5 mL of dry DMF were placed in a small round-bottomed flask under argon atmosphere. The mixture was stirred at room temperature for 3 h and the precipitated urea was then filtered. Residue was taken in  $\text{CH}_2\text{Cl}_2$  and filtered further for any precipitated

urea. This was further washed twice with 0.5N HCL and saturated  $\text{NaHCO}_3$  solution and dried over  $\text{MgSO}_4$  (anhydrous). The Solvent was removed by evaporation and the ester was isolated by distillation/recrystallization. Product obtained was then purified as NIRD1Conjugate. The result

**Fig. 4** Complete reactions for synthesis NIRD1

**Fig. 5** HPLC traces after modification



indicated more than 95% of the dye being converted to active ester.

#### Replacement Na<sup>+</sup> Ion

A solution of Ester **1** (0.8 g, 1.1 mmol) in dry DMF (10 ml) containing triethylamine (0.25 g, 2.5 mmol) was cooled to 0°C. Into this solution 0-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate [TBTU] (0.38 g, 1.2 mmol) dissolved in DMF (2 mL) was added. After 20–30 min of stirring at 0°C a portion of 2 mmol of the D-glucosamine hydrochloride (0.43 g, 1.2 mmol) dissolved in DMF (2 mL) was added. The mixture was allowed to stir for 2 h at room temperature and the following compound with 67% yield was obtained (Fig. 4).

#### Purification and Spectroscopic Analysis


Purification of dyes was performed on a Inertsil ODS preparative HPLC instrument, using a C18-RP preparative

column (flow rate=1 mL/min; eluant A, water with 0.1% TFA; eluant B, 90% of acetonitrile and 10% of eluant A; starting at 90% A for 5 min and then a linear gradient over 40 min to 50% A) [17]. The dual HPLC detector was set at 240 and 360 nm. Dye was collected, and solvent was removed by Speed-vacuum rotary as shown in Fig. 5. The absorbance spectra were measured on a JASCO V-570 spectrophotometer and the fluorescence studies were performed on Perkin Eimer LS-55 Luminiscent spectrometer. The <sup>1</sup>H NMR spectrum was recorded in a 400 MHz VARIAN NMR Spectrometer.

#### NMR Spectroscopy

<sup>1</sup>HNMR (CDCl<sub>3</sub>, 400 MHz) δ 1.62(m, 25H, 5xCH<sub>3</sub> and 2x CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub><sup>-</sup>) 1.66–1.91(m, 12H, Estradiol; β, γ, ω, φ, σ and λ proton positions), 2.91(t, 4H, 2x CH<sub>2</sub>SO<sub>3</sub><sup>-</sup>), 3.37(m, 2H, benzylic protons), 4.2(t, 4H, 2x >NCH<sub>2</sub>), 7.3 (t, 2H, 5'-H), 7.58(d, 2H, 4'-H, 7'-H), 7.72(m, 2H, δ-H, β'-H), 7.89(d, 1H, 6-H), 7.93(dd, 2H, 4-H), 7–8(10H, Aromatic), 8.07(s, 1H, phenolic) (Fig. 6).

**Fig. 6** <sup>1</sup>HNMR (CDCl<sub>3</sub>, 400 MHz) data of NIRDC1



**Table 1** Fluorescent properties of fluochrome prior to tagging (NIRD1)

Compound	Solvent	$\lambda$ max, <i>em</i> (nm)	Stokes' Shift	$\phi^a$
NIRD1	H <sub>2</sub> O	750	38	0.067
	EtOH	753		
	DMSO	750		

<sup>a</sup>Based on ICG as standard ( $\phi=0.13$ )

## Results

### Spectral Properties of NIR Fluorochrome


The NIR Dye was purified by preparative HPLC as described above. The absorbance was measured individually in three dilutions of the stock solution in deionized water or in ethanol (95%) or in DMSO. The fluorescence emission maxima and intensities of the dyes were obtained using dilute solutions in water and exciting at both the main absorption peak as well as the short-wavelength shoulder of the main absorption peak as shown in (Table 1). The quantum yield for NIR Dye1 [NIRD1] was calculated

relative to a standard solution of ICG, with quantum yield of 0.13.

### Spectral Properties of NIRD1 Conjugate

The excitation and emission spectra of NIRD1Conjugate after the replacement of the ion is shown in (Fig. 7). NIRD1Conjugated dye exhibited a 38 nm Stokes' shift of the fluorescence maximum as shown in (Table 2). Quantum yield of the Ester was calculated both in DMSO and PBS and found to be 0.114 and 0.110 respectively. The individual data are given in (Table 2). The absorption and the fluorescence spectra taken in PBS is shown in the

**Fig. 7** Absorption (a) and Fluorescence (b) spectra of NIRD1Conjugate



**Table 2** Fluorescent properties of NIRDC1

Compound	Solvent	$\lambda$ max, <i>abs</i> (nm)	$\lambda$ max, <i>em</i> (nm)	Stokes' Shift	$\phi^*$
NIRD1Con.	DMSO	754	787	33	0.114
NIRD1Con.	PBS	750	788	38	0.110

Based on ICG as standard ( $\phi=0.13$ )

(Fig. 7) (a) and (b) respectively. The fluorescence emission maxima and intensities of the dyes were obtained using dilute Solutions in DMSO and exciting at both the main absorption peak as well as the short-wavelength shoulder of the main absorption peak. In cases of NIRDC1Conjugate the quantum yield was calculated relative to a standard solution of ICG with quantum yield of 0.13 (Table 2). The DyeConjugate exhibited higher molar absorption coefficients with relatively high values of symmetric chemical substitutions.

#### Absorption and Fluorescence Spectra

### Discussion

The characteristics of the DYE1Conjugate (Ester 1) showed a considerable amount of rise in the quantum yield and hydrophilicity. ICG has a poor fluorescence quantum yield (0.012) described for solution in water [22], where as the synthesized ester 1 showed the quantum yield which was at the higher level and did not differ significantly between PBS and DMSO as shown in the (Table 2). The absorption maxima of the conjugate was shifted to a shorter wavelength of 750 as compared to ICG at 780. This we believe is due to the omission of the fused benzene rings of ICG. The increased fluorescence quantum yield of the hydrophilic derivatives reduces the risk of forming the fluorescence-quenched aggregation [16]. Apparently, the interaction within the dye and aggregation is markedly reduced by hydrophilic, non charged substituents. Eventually the change in quantum yield was only insignificant between the solvents used. The test for toxicity was carried out on cell lines MCF-7 and the Ester was found non toxic with 90% viability. At extracellular dye concentrations exceeding 6 mM in equilibrated cell suspensions, both mitochondrial and plasma membrane dye toxicity were observed. Viability and metabolic data demonstrated mutual reinforcement of therapeutic efficacy. The test results reported that both the Dye and the Conjugate were found nontoxic, thereby enabling us to carry out the in-vivo studies.

We are presently involved in testing the fluochrome tagged molecule for imaging of tumors in breast cancer. Thus we believe from these findings that there would be negligible changes in the fluorescence behavior when subjected to in-vivo situation and the fluorescent emission

of the dye is expected to be detectable in high sensitivity above low tissue background [21].

### Conclusion

Our effort to synthesize carbocyanine structurally related to indotricarbocyanine ICG allowed us to study the impact of chemical modification on the optical properties of these compounds. The hydrophilic substitution improved the optical properties of the conjugate as compared to that of the original dye. The conjugate showed an enhanced fluorescence quantum yields in physiological media, which we believe would definitely be useful in carrying out the in-vivo test. Thus the NIRDC1Conjugate (NIRDC1) illustrated in this paper promises to facilitate optical imaging applications where intrinsic contrast between tumor and healthy tissue has to be elevated, predominantly to overcome the restrictions in spatial resolution and sensitivity.

### References

- Li BDL (1994) Estrogen and progesterone receptors: concordance between primary and recurrent breast cancer. *J Surg Oncol* 57:71–99
- Ferlay J, Bray F, Pisani P, Parkin DM (2001) Cancer incidence, mortality and prevalence worldwide, Version 1.0., *Globocan 2000: IARC CancerBase No. 5*. IARC, Lyon
- Tierney LM, Mc Phee SJ, Papadekins MA (1999) Current medical diagnostics and treatment. Appleton and Lange, 683–699
- Chance B (1991) The optical method. *Annu Rev Biophys Chem* 20:1–28
- Hope-Ross M, Yannuzzi LA, Gragoudas ES, Guyer DR, Slakter JS, Sorenson JA (1994) Adverse reactions due to indocyanine green. *Ophthalmology* 101:529–533
- Mordon S, Devoisselle JM, Soulie-Begu S, Desmettre T (1998) Indocyanine green: physicochemical factors affecting its fluorescence in vivo. *Microvasc Res* 55:146–152
- Licha K, Hassenius C, Becker A, Henklein P, Bauer M, Wisniewski S (2001) Synthesis, characterization, and biological properties of cyanine—labeled somatostatin analogues as receptor-targeted fluorescent probes. *Bioconjug Chem* 12:44–50
- Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R (2000) Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. *Invest Radiol* 35:479–485
- O'Leary MA, Boas DA, Li XD, Chance B, Yodh AG (1996) Fluorescence lifetime imaging in turbid media. *Opt Lett* 21:158–160
- De Haller EB (1996) Time-resolved tranillumination and optical tomography. *J Biomed Opt* 1:7–17
- Chang J, Graber HL, Barbour RL (1997) Luminescence optical tomography of dense scattering media. *JOSA A* 14:288–299

12. Franceschini MA, Moesta KT, Fantini S, Gaida G, Gratton E, Jess H, Mantulin WW, Seeber M, Schlag PM, Kaschke M (1997) Frequency-domain techniques enhance optical mammography: initial clinical result. *Proc Natl Acad Sci USA* 94:6468–6473
13. Paithankar DY, Chen AU, Pogue BW, Patterson MS, Sevick-Muraca EM (1997) Imaging of fluorescent yield and lifetime from multiply scattered light reemitted from random media. *Appl Opt* 36:2260–2272
14. Terpetschnig E, Szmacki H, Ozinskas A, Lakowicz JR (1994) Synthesis of squaraine-N-hydroxysuccinimide ester and their biological application as long-wavelength fluorescent labels. *Anal Biochem* 217:197–204
15. Mujumdar RB, Ernst LA, Mujumdar SR, Waggoner AS (1989) Cyanine dye labeling reagents containing isothiocyanate groups. *Cytometry* 10:11–19
16. Mujumdar SR, Mujumdar RB, Grant CM, Waggoner AS (1996) Cyanine-labelling reagents: sulfobenzocyanine succinimidyl ester. *Bioconjug Chem* 7:356–362
17. Lin Y, Weissleder R, Tung CH (2002) Novel near-infrared cyanine fluorochromes: synthesis, properties and bioconjugation. *Bioconjug Chem* 13:605–610
18. Tung C, Mahmood U, Bredow S, Weissleder R (2000) In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. *Cancer Res* 2000:4953–4958
19. Oswald B, Patsenker L, Duschl J, Szmacki H, Wolfbeis OS, Terpetschnig E (1999) Synthesis, spectral properties, and detection limits of reactive squaraine dyes, a new class of diode laser compatible fluorescent protein label. *Bioconjug Chem* 10:925–931
20. Runge VM (1999) Contrast media research. *Investig Radiol* 34:785–790
21. Meijer DKF, Weert B, Vermeer GA (1988) Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. *Eur J Clin Pharmacol* 35:295–303
22. Soper SA, Mattingly QL (1994) Steady-state and picosecond laser fluorescence studies of nonradiative pathways in tricarbo-cyanine dyes: implications to the design of near-IR fluorochromes with high fluorescence efficiencies. *J Am Chem Soc* 116:3744–3752
23. Saunders PTK, Millar MR, Williams K, Macpherson S, Bayne C, O'Sullivan C, Anderson TJ, Groome NP, Miller WR (2002) Expression of oestrogen receptor beta (ER Beta-1) protein in human breast cancer biopsies. *Br J Cancer* 86:250–256
24. Cutler M (1929) Transillumination as an aid in the diagnosis of breast lesions. *Surg Gynecol Obstet* 48:721–729
25. Fantini S, Heffer EL, Franceschini MA, Götz L, Heinig A (1999) Optical mammography with intensity-modulated light, Proceedings Volume from In Vivo Optical Imaging Workshop, September 16–17
26. Padubidri VG, Daftry SN (1999) Hawkins and Bourne; Shaws Textbook of Gynaecology, 12th Edition, 1999, B.I. Churchill Livingstone Pvt. Ltd, New Delhi, Chap. 3. G.Zhang, S.G.Demos, and R.R.Alfano, Far-red and NIR spectral wing emission from tissue under 532-nm and 632-nm photo excitation. *Laser Life Sci* 9:1–16
27. Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W (2000) Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. *Photochem Photobiol* 72:392–398